Clinical trial
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic…
NCT00484276 · AGC Biologics S.p.A., Industry · Completed
Key facts
| NCT number | NCT00484276 |
|---|---|
| Title | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma |
| Official title | NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen |
| Acronym | NGR010 |
| Lead sponsor | AGC Biologics S.p.A., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Pleural Mesothelioma |
| Intervention type | Drug |
| Interventions | NGR-hTNF |
| Enrollment | 57 |
| Start date | May 1, 2007 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Jun 8, 2007 |
| Last update posted | Jan 16, 2019 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: